{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oncology+Patients&page=2", "query": { "condition": "Oncology Patients", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oncology+Patients&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T09:04:44.446Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04684563", "title": "huCART19-IL18 in CD19+ Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Non-hodgkin Lymphoma", "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "huCART19-IL18", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2021-05-06", "completion_date": "2036-05", "has_results": false, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-06-10T09:04:44.446Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04684563" }, { "nct_id": "NCT00864721", "title": "Sunitinib Non Small Cell Lung Cancer Patients Over 70", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Sutent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "US Oncology Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 63, "start_date": "2009-02", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2018-10-16", "last_synced_at": "2026-06-10T09:04:44.446Z", "location_count": 13, "location_summary": "Ocala, Florida • Ocoee, Florida • Minneapolis, Minnesota + 10 more", "locations": [ { "city": "Ocala", "state": "Florida" }, { "city": "Ocoee", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Raleigh", "state": "North Carolina" }, { "city": "Eugene", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00864721" }, { "nct_id": "NCT03761914", "title": "Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia", "Ovarian Cancer", "Colorectal Cancer", "Triple-negative Breast Cancer", "Small-cell Lung Cancer" ], "interventions": [ { "name": "galinpepimut-S", "type": "BIOLOGICAL" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Montanide", "type": "OTHER" }, { "name": "GM-CSF", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Sellas Life Sciences Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2019-09-30", "completion_date": "2022-10-27", "has_results": true, "last_update_posted_date": "2024-11-19", "last_synced_at": "2026-06-10T09:04:44.446Z", "location_count": 12, "location_summary": "Santa Rosa, California • Whittier, California • Miami, Florida + 9 more", "locations": [ { "city": "Santa Rosa", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03761914" }, { "nct_id": "NCT05125016", "title": "A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "REGN4336", "type": "DRUG" }, { "name": "REGN5678", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 228, "start_date": "2021-11-30", "completion_date": "2030-03-28", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-06-10T09:04:44.446Z", "location_count": 13, "location_summary": "Palo Alto, California • New Haven, Connecticut • Louisville, Kentucky + 8 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05125016" }, { "nct_id": "NCT00987649", "title": "Ovarian Cancer Risk Estimation in Patients With Pelvic Mass", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adnexal Mass", "Ovarian Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Fujirebio Diagnostics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 512, "start_date": "2009-10", "completion_date": "2010-09", "has_results": false, "last_update_posted_date": "2011-02-09", "last_synced_at": "2026-06-10T09:04:44.446Z", "location_count": 13, "location_summary": "San Diego, California • Fort Collins, Colorado • Jupiter, Florida + 10 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Jupiter", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00987649" }, { "nct_id": "NCT00003849", "title": "Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "1999-07", "completion_date": "2008-02", "has_results": false, "last_update_posted_date": "2016-07-13", "last_synced_at": "2026-06-10T09:04:44.446Z", "location_count": 20, "location_summary": "Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 17 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Cedar Rapids", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003849" }, { "nct_id": "NCT02110849", "title": "Prostate Cancer Parameters for Patients Receiving Proton Treatment", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Proton", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 0, "start_date": "2013-01", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2016-04-07", "last_synced_at": "2026-06-10T09:04:44.446Z", "location_count": 1, "location_summary": "Bloomington, Indiana", "locations": [ { "city": "Bloomington", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02110849" }, { "nct_id": "NCT06607458", "title": "Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab", "type": "DRUG" }, { "name": "Trifluridine-tipiracil plus Bevacizumab Alone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Delcath Systems Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2025-08-05", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-06-10T09:04:44.446Z", "location_count": 6, "location_summary": "Duarte, California • Santa Monica, California • Tampa, Florida + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Fairway", "state": "Kansas" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06607458" }, { "nct_id": "NCT05054348", "title": "First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "IO-108", "type": "BIOLOGICAL" }, { "name": "IO-108 + pembrolizumab combination therapy", "type": "BIOLOGICAL" }, { "name": "IO-108 + cemiplimab combination therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Immune-Onc Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2021-09-30", "completion_date": "2024-05-31", "has_results": false, "last_update_posted_date": "2024-06-04", "last_synced_at": "2026-06-10T09:04:44.446Z", "location_count": 24, "location_summary": "Tucson, Arizona • Beverly Hills, California • Lone Tree, Colorado + 20 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Lake Mary", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05054348" }, { "nct_id": "NCT07478848", "title": "Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Large B Cell Lymphoma", "Non Hodgkin Lymphoma (NHL)", "Diffuse Large B Cell Lymphoma (DLBCL)", "Diffuse Large B Cell Lymphoma Refractory", "Diffuse Large B Cell Lymphoma Relapsed" ], "interventions": [ { "name": "Vancomycin 125mg", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "CAR-T", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2026-05-27", "completion_date": "2029-01-01", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-06-10T09:04:44.446Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07478848" } ] }